Cargando…

Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies

Epidermal growth factor receptor (EGFR) inhibitors are widely used to treat various types of cancers such as non-small cell lung cancer, head and neck cancer, breast cancer, pancreatic cancer. Adverse reactions such as skin toxicity, interstitial lung disease, hepatotoxicity, ocular toxicity, hypoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yanping, Fu, Ruoqiu, Jiang, Tingting, Duan, Dongyu, Wu, Yuanlin, Li, Chen, Li, Ziwei, Ni, Rui, Li, Li, Liu, Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866822/
https://www.ncbi.nlm.nih.gov/pubmed/35223483
http://dx.doi.org/10.3389/fonc.2022.804212
_version_ 1784655915672141824
author Li, Yanping
Fu, Ruoqiu
Jiang, Tingting
Duan, Dongyu
Wu, Yuanlin
Li, Chen
Li, Ziwei
Ni, Rui
Li, Li
Liu, Yao
author_facet Li, Yanping
Fu, Ruoqiu
Jiang, Tingting
Duan, Dongyu
Wu, Yuanlin
Li, Chen
Li, Ziwei
Ni, Rui
Li, Li
Liu, Yao
author_sort Li, Yanping
collection PubMed
description Epidermal growth factor receptor (EGFR) inhibitors are widely used to treat various types of cancers such as non-small cell lung cancer, head and neck cancer, breast cancer, pancreatic cancer. Adverse reactions such as skin toxicity, interstitial lung disease, hepatotoxicity, ocular toxicity, hypomagnesemia, stomatitis, and diarrhea may occur during treatment. Because the EGFR signaling pathway is important for maintaining normal physiological skin function. Adverse skin reactions occurred in up to 90% of cancer patients treated with EGFR inhibitors, including common skin toxicities (such as papulopustular exanthemas, paronychia, hair changes) and rare fatal skin toxicities (e.g., Stevens–Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis). This has led to the dose reduction or discontinuation of EGFR inhibitors in the treatment of cancer. Recently, progress has been made about research on the skin toxicity of EGFR inhibitors. Here, we summarize the mechanism of skin toxicity caused by EGFR inhibitors, measures to prevent severe fatal skin toxicity, and provide reference for medical staff how to give care and treatment after adverse skin reactions.
format Online
Article
Text
id pubmed-8866822
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88668222022-02-25 Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies Li, Yanping Fu, Ruoqiu Jiang, Tingting Duan, Dongyu Wu, Yuanlin Li, Chen Li, Ziwei Ni, Rui Li, Li Liu, Yao Front Oncol Oncology Epidermal growth factor receptor (EGFR) inhibitors are widely used to treat various types of cancers such as non-small cell lung cancer, head and neck cancer, breast cancer, pancreatic cancer. Adverse reactions such as skin toxicity, interstitial lung disease, hepatotoxicity, ocular toxicity, hypomagnesemia, stomatitis, and diarrhea may occur during treatment. Because the EGFR signaling pathway is important for maintaining normal physiological skin function. Adverse skin reactions occurred in up to 90% of cancer patients treated with EGFR inhibitors, including common skin toxicities (such as papulopustular exanthemas, paronychia, hair changes) and rare fatal skin toxicities (e.g., Stevens–Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis). This has led to the dose reduction or discontinuation of EGFR inhibitors in the treatment of cancer. Recently, progress has been made about research on the skin toxicity of EGFR inhibitors. Here, we summarize the mechanism of skin toxicity caused by EGFR inhibitors, measures to prevent severe fatal skin toxicity, and provide reference for medical staff how to give care and treatment after adverse skin reactions. Frontiers Media S.A. 2022-02-10 /pmc/articles/PMC8866822/ /pubmed/35223483 http://dx.doi.org/10.3389/fonc.2022.804212 Text en Copyright © 2022 Li, Fu, Jiang, Duan, Wu, Li, Li, Ni, Li and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Yanping
Fu, Ruoqiu
Jiang, Tingting
Duan, Dongyu
Wu, Yuanlin
Li, Chen
Li, Ziwei
Ni, Rui
Li, Li
Liu, Yao
Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies
title Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies
title_full Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies
title_fullStr Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies
title_full_unstemmed Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies
title_short Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies
title_sort mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866822/
https://www.ncbi.nlm.nih.gov/pubmed/35223483
http://dx.doi.org/10.3389/fonc.2022.804212
work_keys_str_mv AT liyanping mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies
AT furuoqiu mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies
AT jiangtingting mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies
AT duandongyu mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies
AT wuyuanlin mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies
AT lichen mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies
AT liziwei mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies
AT nirui mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies
AT lili mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies
AT liuyao mechanismoflethalskintoxicitiesinducedbyepidermalgrowthfactorreceptorinhibitorsandrelatedtreatmentstrategies